Last reviewed · How we verify
Intra-amniotic injection of DIGOXIN
Intra-amniotic injection of DIGOXIN is a Cardiac glycoside Small molecule drug developed by Meir Medical Center. It is currently in Phase 3 development for Fetal supraventricular tachycardia, Fetal atrial flutter.
Intra-amniotic digoxin administration aims to treat fetal cardiac arrhythmias by crossing fetal membranes and exerting direct cardiac glycoside effects on fetal myocardium.
Intra-amniotic digoxin administration aims to treat fetal cardiac arrhythmias by crossing fetal membranes and exerting direct cardiac glycoside effects on fetal myocardium. Used for Fetal supraventricular tachycardia, Fetal atrial flutter.
At a glance
| Generic name | Intra-amniotic injection of DIGOXIN |
|---|---|
| Sponsor | Meir Medical Center |
| Drug class | Cardiac glycoside |
| Target | Na+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Cardiology |
| Phase | Phase 3 |
Mechanism of action
Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing myocardial contractility while also slowing AV nodal conduction. When injected into amniotic fluid, digoxin diffuses across fetal membranes to reach fetal circulation, allowing direct treatment of fetal arrhythmias without systemic maternal administration. This route may provide higher fetal concentrations while potentially reducing maternal side effects.
Approved indications
- Fetal supraventricular tachycardia
- Fetal atrial flutter
Common side effects
- Maternal digoxin toxicity
- Fetal bradycardia
- Amniotic fluid infection/chorioamnionitis
- Premature rupture of membranes
Key clinical trials
- Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy (PHASE3)
- A Trial of Digoxin Before Second-Trimester Abortion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-amniotic injection of DIGOXIN CI brief — competitive landscape report
- Intra-amniotic injection of DIGOXIN updates RSS · CI watch RSS
- Meir Medical Center portfolio CI
Frequently asked questions about Intra-amniotic injection of DIGOXIN
What is Intra-amniotic injection of DIGOXIN?
How does Intra-amniotic injection of DIGOXIN work?
What is Intra-amniotic injection of DIGOXIN used for?
Who makes Intra-amniotic injection of DIGOXIN?
What drug class is Intra-amniotic injection of DIGOXIN in?
What development phase is Intra-amniotic injection of DIGOXIN in?
What are the side effects of Intra-amniotic injection of DIGOXIN?
What does Intra-amniotic injection of DIGOXIN target?
Related
- Drug class: All Cardiac glycoside drugs
- Target: All drugs targeting Na+/K+-ATPase
- Manufacturer: Meir Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiology
- Indication: Drugs for Fetal supraventricular tachycardia
- Indication: Drugs for Fetal atrial flutter
- Compare: Intra-amniotic injection of DIGOXIN vs similar drugs
- Pricing: Intra-amniotic injection of DIGOXIN cost, discount & access